Acceleron Pharma (XLRN) Stock Price, News & Analysis

Company Overview

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

Key Stats

• Today's Range: $178.75 to $178.75
• 50-Day Range: $172.08 to $179.68
• 52-Week Range: $108.82 to $189.99
• Volume: N/A
• Average Volume: 572,759 shs
• Market Capitalization: $10.93 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

XLRN Stock Analysis - Frequently Asked Questions

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc. (NASDAQ:XLRN) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($0.98) by $0.18. The firm's revenue for the quarter was up 51.6% on a year-over-year basis.

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA) and Vertex Pharmaceuticals (VRTX).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 4/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:XLRN
• CIK: 1280600
• Web: www.acceleronpharma.com
• Phone: (617) 649-9200
• Fax: 617-649-9988
• Employees: 312
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-166,030,000.00
• Net Margins: -226.01%
• Pretax Margin: -225.99%
• Return on Equity: -32.11%
• Return on Assets: -29.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.14
• Quick Ratio: 12.14

Sales & Book Value

• Annual Sales: $92.52 million
• Price / Sales: 118.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.74 per share
• Price / Book: 15.23

Miscellaneous

• Outstanding Shares: 61,156,000
• Free Float: 60,116,000
• Market Cap: $10.93 billion
• Optionable: Optionable
• Beta: 0.13